SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
Children with standard-risk hepatoblastoma were cured just as often with cisplatin alone as with cisplatin plus doxorubicin, and had far fewer severe side effects, so doxorubicin can be left out.
Overview
International randomised trial of the SIOPEL group: 255 children with standard-risk hepatoblastoma were randomised to pre- and post-operative cisplatin alone (n 126) or cisplatin plus doxorubicin (n 129) with delayed resection.
Complete resection was achieved in 95 and 93 percent; three-year event-free survival was 83 and 85 percent and overall survival 95 and 93 percent (median follow-up 46 months). Acute grade 3 or 4 adverse events occurred in 20.6 percent with cisplatin alone against 74.4 percent with the combination.
- Complete resection 95 percent with cisplatin versus 93 percent with cisplatin plus doxorubicin (difference 1.4 percent, 95% CI -4.1 to 7.0).
- Three-year event-free survival 83 versus 85 percent; overall survival 95 versus 93 percent.
- Grade 3 or 4 acute adverse events 20.6 versus 74.4 percent.
Cisplatin monotherapy with delayed surgery is the standard for standard-risk hepatoblastoma; later SIOPEL-6 added sodium thiosulfate to protect hearing.
- Standard-risk disease only; high-risk patients need intensified regimens such as SIOPEL-4.
Similar pages
not linked directly; found by shared links- Key paperSIOPEL-4: dose-dense cisplatin-based chemotherapy and surgery for high-risk hepatoblastoma
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
- TermPRETEXT and CHIC risk groups (hepatoblastoma)
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
- TrialSIOPEL-4
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
- Key paperFIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma
Shares Doxorubicin, Cisplatin, New England Journal of Medicine.
- Key paperGHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma
- Key paperRAPID: PET-directed therapy for early-stage Hodgkin lymphoma
- Key paperRATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma
- TrialPerioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Shares Doxorubicin, Cisplatin.